Filing Details
- Accession Number:
- 0000899243-18-009260
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-04-03 17:07:57
- Reporting Period:
- 2018-04-03
- Accepted Time:
- 2018-04-03 17:07:57
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1622229 | Unum Therapeutics Inc. | UMRX | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1451612 | Bruce Booth | C/O Unum Therapeutics Inc. 200 Cambridge Park Drive, Suite 3100 Cambridge MA 02140 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-04-03 | 3,184,446 | $0.00 | 3,184,446 | No | 4 | C | Indirect | See Footnote |
Common Stock | Acquisiton | 2018-04-03 | 83,037 | $0.00 | 3,267,483 | No | 4 | C | Indirect | See Footnote |
Common Stock | Acquisiton | 2018-04-03 | 94,052 | $12.00 | 3,361,535 | No | 4 | P | Indirect | See Footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Indirect | See Footnote |
No | 4 | C | Indirect | See Footnote |
No | 4 | P | Indirect | See Footnote |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A Preferred Stock | Disposition | 2018-04-03 | 3,184,446 | $0.00 | 3,184,446 | $0.00 |
Common Stock | Series B Preferred Stock | Disposition | 2018-04-03 | 83,037 | $0.00 | 83,037 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Indirect | ||
0 | No | 4 | C | Indirect |
Footnotes
- Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date.
- The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Dr. Booth is a member of AVA IX LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund IX, except to the extent of his pecuniary interest therein, if any.